{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:25:00Z","timestamp":1790846700995,"version":"4.1.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Hum. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>About one-third of adults have trouble sleeping, ranging from occasional difficulty to chronic insomnia, along with difficulty maintaining sleep. Many studies reported that the long-term use of hypnotics can cause brain dysfunction and damage cognition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of the study is to evaluate whether low, medium, and high doses of orexin dual receptor antagonists (DORA), zopiclone (ZOP), eszopiclone (ESZ), and zolpidem (ZST) can impair cognition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From the beginning through September 20, 2022, PubMed, Embase, Scopus, the Cochrane Library, and Google Scholar were searched. Randomized controlled trials (RCTs) assessing the therapeutic effects of DORA, eszopiclone, and zopiclone for sleep and cognitive function were included. The primary outcomes were indices related to the cognitive profile, including memory, alertness, execution and control function, and attention and orientation. The secondary outcomes were indices related to sleep and adverse events. The standard mean difference (SMD) was generated for continuous variables. Certain data were captured from figures by GetData 2.26 and analyzed using RStudio 4.2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Finally, a total of 8,702 subjects were included in 29 studies. Compared with the placebo, the DSST (Digit Symbol Substitution Test) scores of low, medium, and high doses of DORA were SMD = 0.77; 95% CI: 0.33\u20131.20; SMD = 1.58; 95% CI: 1.11\u20132.05; and SMD = 0.85; 95% CI: 0.33\u20131.36, respectively. The DSST scores of zolpidem at low, medium, and high doses were SMD = \u22120.39; 95% CI: 0.85\u20130.07; SMD = \u22120.88, 95% CI: \u22122.34\u20130.58; and SMD = \u22120.12, 95% CI: \u22120.85\u20130.60, respectively. Zopiclone's DSST scale score was SMD = \u22120.18; 95% CI: \u22120.54\u20130.18. In addition, the total sleep time (TST) of low, medium, and high doses of DORA was SMD = 0.28, 95% CI: \u22120.15\u20130.70; SMD = 1.36, 95% CI: 0.87\u20131.86; and SMD = 2.59, 95% CI: 1.89\u20133.30, respectively. The TST of zolpidem with low, medium, and high doses was SMD = 1.01, 95% CI: 0.18\u20131.83; SMD = 1.94, 95% CI: 0.46\u20133.43; and SMD = 1.71, 95% CI: 0.86\u20132.56, respectively. The TST of low, medium, and high doses of eszopiclone was relatively SMD = 2.03, 95% CI: \u22120.21\u20134.27; SMD = 2.38, 95% CI: 1.35\u20133.42; and SMD = 1.71, 95% CI: 0.60\u20132.82. Zopiclone's TST was SMD = 2.47, 95% CI: 1.36\u20133.58.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We recommend DORA as the best intervention for insomnia because it is highly effective in inducing and maintaining sleep without impairing cognition. Although zolpidem has a more pronounced effect on maintaining sleep, it is best to reduce its use because of its side effects. Eszopiclone and zopiclone improved sleep quality, but their safety in cognition remains to be verified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnhum.2022.1029554","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T10:55:12Z","timestamp":1673348112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Mengzhen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyou","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1016\/j.parkreldis.2015.09.034","article-title":"Cognitive impairment in Parkinson's disease and dementia with Lewy bodies","volume":"22","author":"Aarsland","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/sleep\/33.2.225","article-title":"A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep\/wake function in older adults with primary and comorbid insomnia","volume":"33","author":"Ancoli-lsrael","year":"2010","journal-title":"Sleep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.5665\/sleep.1996","article-title":"The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia","volume":"35","author":"Bettica","year":"2012","journal-title":"Sleep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/JCP.0000000000001439","article-title":"Effects of bedtime dosing with suvorexant and zolpidem on balance and psychomotor performance in healthy elderly participants during the night and in the morning","volume":"41","author":"Bland","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsaa275","article-title":"Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea","volume":"44","author":"Boof","year":"2021","journal-title":"Sleep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1590\/1516-4446-2019-0389","article-title":"Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial","volume":"42","author":"Castro","year":"2020","journal-title":"Braz. J. Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"119147","DOI":"10.1016\/j.lfs.2021.119147","article-title":"Cognitive behavioral therapy for insomnia in veterans with gulf war illness: results from a randomized controlled trial","volume":"279","author":"Chao","year":"2021","journal-title":"Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"pyw022","DOI":"10.1093\/ijnp\/pyw022","article-title":"A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia","volume":"19","author":"Connor","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder","volume":"87","author":"Dauvilliers","year":"2020","journal-title":"Ann. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"g5205","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and risk of Alzheimer's disease: case-control study","volume":"349","author":"De Gage","year":"2014","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.37765\/ajmc.2020.42769","article-title":"Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy","volume":"26","author":"Dopheide","year":"2020","journal-title":"Am. J. Manag. Care."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.5664\/jcsm.7920","article-title":"Can the orexin antagonist suvorexant preserve the ability to awaken to auditory stimuli while improving sleep?","volume":"15","author":"Drake","year":"2019","journal-title":"J. Clin. Sleep Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neuro.2021.02.005","article-title":"Effect of suvorexant on morphine tolerance and dependence in mice: role of NMDA, AMPA, ERK and CREB proteins","volume":"84","author":"Esmaili-Shahzade-Ali-Akbari","year":"2021","journal-title":"Neurotoxicology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/B978-0-12-397220-0.00011-8","article-title":"Zolpidem tartrate","volume":"37","author":"Foda","year":"2012","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz241","article-title":"The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model","volume":"43","author":"Gamble","year":"2020","journal-title":"Sleep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.14423\/SMJ.0000000000000769","article-title":"Cognitive behavioral therapy in the treatment of Insomnia","volume":"111","author":"Haynes","year":"2018","journal-title":"South Med. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial","volume":"16","author":"Herring","year":"2020","journal-title":"Alzheimers Dement"},{"key":"B18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2014","journal-title":"Biol. Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.5664\/jcsm.6116","article-title":"Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials","volume":"12","author":"Herring","year":"2016","journal-title":"J. Clin. Sleep Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","article-title":"Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials","volume":"25","author":"Herring","year":"2017","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.sleep.2013.04.010","article-title":"Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study","volume":"14","author":"Herring","year":"2013","journal-title":"Sleep Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2165\/00023210-200317070-00004","article-title":"Clinically important drug interactions with zopiclone, zolpidem and zaleplon","volume":"17","author":"Hesse","year":"2003","journal-title":"CNS Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/0269881112448946","article-title":"Orexin receptor antagonism: an ascending multiple-dose study with almorexant","volume":"26","author":"Hoever","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/JCP.0b013e31828f5a7a","article-title":"Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects","volume":"33","author":"Hoever","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2165\/00003495-200059040-00014","article-title":"Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia","volume":"59","author":"Holm","year":"2000","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.npep.2013.10.009","article-title":"Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?","volume":"47","author":"Hoyer","year":"2013","journal-title":"Neuropeptides"},{"key":"B28","author":"Julie","year":"2020","journal-title":"BCPP, FASHP, Insomnia Overview: Epidemiology, Pathophysiology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"Karppa","year":"2020","journal-title":"Sleep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/7854_2016_49","article-title":"Orexin\/hypocretin signaling","volume":"33","author":"Kukkonen","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.pharep.2015.09.002","article-title":"Emerging role of orexin antagonists in insomnia therapeutics: an update on SORAs and DORAs","volume":"68","author":"Kumar","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1007\/s00213-014-3447-z","article-title":"Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study","volume":"231","author":"Leufkens","year":"2014","journal-title":"Psychopharmacology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41386-021-01191-3","article-title":"The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial","volume":"47","author":"Louzada","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5664\/jcsm.27872","article-title":"Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. J. Clin","volume":"6","author":"McCall","year":"2010","journal-title":"Sleep Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/mds.23168","article-title":"Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo","volume":"25","author":"Menza","year":"2010","journal-title":"Mov. Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.5665\/SLEEP.1272","article-title":"Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects","volume":"34","author":"Mets","year":"2011","journal-title":"Sleep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ajim.4700150608","article-title":"Choice (CRT) and simple reaction times (SRT) compared in laboratory technicians: factors influencing reaction times and a predictive model. Am","volume":"15","author":"Miller","year":"1989","journal-title":"J. Ind. Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5664\/jcsm.8294","article-title":"Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening","volume":"16","author":"Murphy","year":"2020","journal-title":"J. Clin. Sleep Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/7854_2015_425","article-title":"Benzodiazepines","volume":"34","author":"Nielsen","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.smrv.2017.03.005","article-title":"Cognitive deficits in obstructive sleep apnea: insights from a meta-review and comparison with deficits observed in COPD, insomnia, and sleep deprivation","volume":"38","author":"Olaithe","year":"2018","journal-title":"Sleep Med. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B42","doi-asserted-by":"publisher","first-page":"170629","DOI":"10.1016\/j.peptides.2021.170629","article-title":"Do orexin\/hypocretin neurons signal stress or reward?","volume":"145","author":"Peleg-Raibstein","year":"2021","journal-title":"Peptides"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.2146\/ajhp160381","article-title":"Benzodiazepine use and cognitive decline in the elderly","volume":"75","author":"Picton","year":"2018","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.conb.2013.04.007","article-title":"Orexin deficiency and narcolepsy","volume":"23","author":"Sakurai","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40265-020-01276-1","article-title":"Lemborexant: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"24353","DOI":"10.1073\/pnas.1907354116","article-title":"Distinct effects of orexin receptor antagonist and GABAA agonist on sleep and physical\/cognitive functions after forced awakening","volume":"116","author":"Seol","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1179\/0886963414Z.00000000084","article-title":"Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta\u00ae) and its effect on total sleep time, headache frequency, and daytime functioning: a randomized, double-blind, placebo-controlled, parallel-group, pilot study","volume":"33","author":"Spierings","year":"2015","journal-title":"Cranio"},{"key":"B49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1037\/a0026198","article-title":"Dopaminergic and cholinergic modulations of visual-spatial attention and working memory: insights from molecular genetic research and implications for adult cognitive development","volume":"48","author":"Stormer","year":"2012","journal-title":"Dev. Psychol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/13803395.2014.928268","article-title":"The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis","volume":"36","author":"Stranks","year":"2014","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"146359","DOI":"10.1016\/j.brainres.2019.146359","article-title":"Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder","volume":"1731","author":"Suchting","year":"2020","journal-title":"Brain Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/archdischild-2014-306764","article-title":"Cognitive dysfunction in adolescents with chronic fatigue: a cross-sectional study","volume":"100","author":"Sulheim","year":"2015","journal-title":"Arch. Dis. Child."},{"key":"B54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5665\/sleep.2386","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","volume":"36","author":"Sun","year":"2013","journal-title":"Sleep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.schres.2014.10.002","article-title":"The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"Tek","year":"2014","journal-title":"Schizophr. Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00002018-200326040-00004","article-title":"New drugs for insomnia","volume":"26","author":"Terzano","year":"2003","journal-title":"Drug Safety"},{"key":"B57","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000514960","article-title":"Sleep, orexin and cognition","volume":"45","author":"Toor","year":"2021","journal-title":"Front. Neurol. Neurosci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.sleep.2012.08.015","article-title":"A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia","volume":"13","author":"Uchimura","year":"","journal-title":"Sleep Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1744-859X-11-15","article-title":"Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study","volume":"11","author":"Uchimura","year":"","journal-title":"Ann. Gen. Psychiatry"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsy260","article-title":"On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers","author":"Vermeeren","year":"2019","journal-title":"Sleep"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00213-016-4375-x","article-title":"On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly","volume":"233","author":"Vermeeren","year":"2016","journal-title":"Psychopharmacology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"489","DOI":"10.5665\/sleep.3482","article-title":"Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use","volume":"37","author":"Vermeeren","year":"2014","journal-title":"Sleep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/NMD.0000000000001074","article-title":"Zolpidem-associated consequences: an updated literature review with case reports","volume":"208","author":"Westermeyer","year":"2020","journal-title":"J. Nerv. Ment. Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Zammit","year":"2020","journal-title":"Neurology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa084","article-title":"The effect of zolpidem on memory consolidation over a night of sleep","author":"Zhang","year":"2020","journal-title":"Sleep"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e12383","DOI":"10.1097\/MD.0000000000012383","article-title":"Cognitive behavioral therapy for insomnia combined with eszopiclone for the treatment of sleep disorder patients transferred out of the intensive care unit: a single-centred retrospective observational study","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine"},{"key":"B67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neurobiolaging.2020.02.020","article-title":"Suvorexant ameliorates cognitive impairments and pathology in APP\/PS1 transgenic mice","volume":"91","author":"Zhou","year":"2020","journal-title":"Neurobiol. Aging"}],"container-title":["Frontiers in Human Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnhum.2022.1029554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T10:55:14Z","timestamp":1673348114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnhum.2022.1029554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":67,"alternative-id":["10.3389\/fnhum.2022.1029554"],"URL":"https:\/\/doi.org\/10.3389\/fnhum.2022.1029554","relation":{},"ISSN":["1662-5161"],"issn-type":[{"value":"1662-5161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1029554"}}